New book by Larry Connors Click here Improve your trading - See how
Memory Pharmaceuticals Corp. (NASDAQ: MEMY | Quote | Chart | News | PowerRating) a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company's products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer's disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer's disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer's disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was founded in 1997 and is based in Montvale, New Jersey. With 77.5 million shares outstanding and 33,300 shares declared short as of October 2008, there is a failure to deliver in shares of MEMY. According to quarterly data provided by the SEC, there were still 1,168,298 shares of MEMY that were failing-to-deliver as of October 24, 2007.
Merriman Curhan Ford Group Inc (NASDAQ: MERR | Quote | Chart | News | PowerRating) through its subsidiaries, provides investment banking, institutional brokerage, equity research, and asset management services to institutional investors and corporate clients in the United States. Its investment banking services include advising on and structuring capital raising solutions for corporate clients through public and private offerings of primarily equity and convertible debt securities. The company also provides strategic advisory services, including transaction specific advice regarding mergers and acquisitions, divestitures, spin-offs, and privatizations, as well as general strategic advice. Merriman Curhan Ford Group's institutional brokerage services include institutional sales, sales trading, and trading services; and executing securities transactions for money managers, mutual funds, hedge funds, insurance companies, and pension and profit-sharing plans. The company also undertakes equity research of fast growing companies operating in technology, telecommunications, next-generation energy, health care, and consumer sectors. Its asset management operations include creating and managing investment products for institutional and high-net worth clients. Merriman Curhan Ford Group was formerly known as MCF Corporation. The company was founded in 1987 and is headquartered in San Francisco, California with additional offices in New York, New York; Newport Beach, California; and Portland, Oregon. With 12.86 million shares outstanding and 870,600 shares declared short as of October 2008, there is a failure to deliver in shares of MERR. According to quarterly data provided by the SEC, there were still 215,328 shares of MERR that were failing-to-deliver as of June 10, 2008.
Texas Petrochemicals Inc (OTC: TXPI | Quote | Chart | News | PowerRating) provides C4 processing and performance chemicals to chemical and petroleum based companies worldwide. The company's products include butadiene, which is used to produce synthetic rubber; n-butylenes (butene-1) that is used in the manufacture of plastic resins, fuel additives, and synthetic alcohols; raffinates, which are used in gasoline blend stock formations; and isobutylenes that is used in the production of specialty rubbers, lubricant additives, detergents, and coatings. It also offers polyisobutylenes, which is used in the production of fuel and lubricant additives, adhesives, sealants, and packaging; and propylene derivatives that are used in the production of plasticizes, surfactants, and rubber additives. The company is headquartered in Houston, Texas. With 17.80 million shares outstanding and 39,200 shares declared short as of October 2008, there is a failure to deliver in shares of TXPI. According to quarterly data provided by the SEC, there were still 1,137,893 shares of TXPI that were failing-to-deliver as of March 6, 2008.
Solvay S.A. Ordinary A (OTC: SVYSY | Quote | Chart | News | PowerRating) operates as a chemical and pharmaceutical group that engages in pharmaceutical, chemical, and plastic activities worldwide. It operates in three segments: Pharmaceuticals, Chemicals, and Plastics. The Pharmaceuticals segment engages in the research, development, and commercialization of products for the treatment of cardiometabolics, such as dyslipidemia, obesity, type 2 diabetes, congestive heart failure, renal insufficiency, and atrial fibrillation; neuroscience, including schizophrenia, Parkinson's disease, traumatic brain injury, and cognition; and flu vaccines and pancreatic enzymes. It primarily offers TRICOR/LIPANTHYL and TEVETEN for cardiometabolics; ANDROGEL for men's health; CREON pancreatic enzymes; SERC and MARINOL for neuroscience therapeutic field; and INFLUVAC, a flu vaccine. This segment also involves in commercial franchises of the products used for gastroenterology; and women's and men's health. In addition, it has a portfolio of products in various phases of development in its therapeutic areas. The Chemicals segment offers minerals, such as soda ash and derivatives, and precipitated calcium carbonate; fluorinated products, and electrochemicals and derivatives; hydrogen peroxide, detergents, and caprolactones; and organic solutions, such as oligonucleotide and peptide compounds. The Plastics segment offers fluorinated polymers, elastomers and fluids, barrier materials, polyarylamides, polysulfones, high performance polyamides, and liquid crystal polymers; inergy automotive fuel systems; and integrated electrolysis chain, vinyl chloride monomers, poly vinyl chloride polymers, and PVC compounds. Solvay S.A. primarily serves glass, chemical, paper, construction and architecture, human health, human and animal food processing, packaging, water and environment, automobile, electricity and electronics, and consumer goods industries. The company was founded in 1863 and is headquartered in Brussels, Belgium. With 84.70 million shares outstanding and 3,500 shares declared short as of October 2008, there is a failure to deliver in shares of SVYSY.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,300,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
